LifeStance Health Group (LFST) disclosed that director Jeffrey Rhodes resigned on July 2, 2026, with no disagreement behind his departure. The board immediately appointed three new directors—Thurman Justice, Lori Goltermann, and Safwan Shabab—to fill the vacancies. Justice and Goltermann each received an initial award of 35,492 restricted stock units that vest based on time and performance. The new directors have been assigned to audit, compensation, and governance committees.

View Full Filing (SEC EDGAR)

View all Form 8-K filings

FAQ

Who are the top institutional investors holding LIFESTANCE HEALTH GROUP INC (LFST)?

Major stakeholders currently include Tpg Gp A, LLC ($892.0M), FMR LLC ($373.8M), Summit Partners L P ($186.1M). Based on the latest 13F filings, there are a total of 226 tracked investment funds and institutions maintaining positions in LFST.

What is the overall institutional sentiment toward LFST recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $284.7M, driven by 134 managers accumulating shares while 78 reduced their exposure.

Which institutions have been selling or reducing their LFST positions?

In the latest period, 54 funds trimmed their holdings, and 24 managers completely exited their positions. The aggregate reported sell value was $1.8B.

Are there any notable investors adding LFST to their portfolios?

Yes, buying activity remains notable. 42 institutions opened new positions in {ticker}, and 92 existing holders added to their shares. The total reported buy value for the quarter amounted to $833.9M.